Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Translating state-of-the-art spinal cord MRI techniques to clinical use: A systematic review of clinical studies utilizing DTI, MT, MWF, MRS, and fMRI.
Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome.
Isolation of Clostridium perfringens Type B in an Individual at First Clinical Presentation of Multiple Sclerosis Provides Clues for Environmental Triggers of the Disease.
Biomarkers for Brain Disorders: Challenges and Opportunities
Clinical utility of the list sign as a predictor of non-demyelinating disorders in a multiple sclerosis (MS) practice.
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid.
Opinion: Sex inclusion in basic research drives discovery.
Clinically feasible MTR is sensitive to cortical demyelination in MS.
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
Dimethylfumarate protects against TNF-α-induced secretion of inflammatory cytokines in human endothelial cells.
IL-17 and GM-CSF Expression Are Antagonistically Regulated by Human T Helper Cells.
Receptos to initiate Phase 3 trial of RPC1063 in relapsing multiple sclerosis
NOVANTRONE. mitoXANTRONE for injection concentrate
Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication.
Architecture of human mTOR complex 1.
Limit cycle oscillations in standing human posture.
Antioxidative enzymes activity and malondialdehyde concentration during mitoxantrone therapy in multiple sclerosis patients.
Flupirtine
Berlex continues legal challenge to FDA over MS drug.
Oligodendrogenesis and myelinogenesis during postnatal development effect of glatiramer acetate.
The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro.
Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?
Oral Laquinimod for Multiple Sclerosis Treatment Significantly Reduced Disease Activity and Disability Progression While Providing Good Safety and Tolerability
Merck: Regulatory Update on Cladribine Tablets
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results.

Pages